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Deep vein thrombosis (DVT) is a common disease and is associated with pulmonary embolism (PE). Proximal
iliofemoral DVT may lead to severe PE and chronic venous insufficiency. The standard therapy for DVT is anticoagulant
therapy using heparin and a vitamin K antagonist, but a recent clinical study showed that rivaroxaban, an oral Xa
inhibitor, was comparable to standard therapy and had less bleeding complications. Intensive high-dose anticoagulation
is recommended during the initial 3 weeks of DVT treatment. The present report describes a case of a 77-year-old
male showing a remarkable regression of DVT in response to rivaroxaban treatment within the initial 3 weeks of therapy
and who did not experience any adverse events. His DVT was massive and was accompanied by proximal iliofemoral
vein thrombus and iliac vein compression syndrome. Rivaroxaban, especially in intensive high-dose treatment,
might be a safe and effective therapeutic choice for massive DVT.
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Venous thromboembolism (VTE), including deep vein
thrombosis (DVT) and pulmonary embolism (PE), is a
common medical condition and is the third leading
cause of cardiovascular death [1]. The clinical severity of
DVT is associated with the burden and location of the
venous thrombus. Patients with proximal iliofemoral
DVT are most likely to have early and late morbidity [2].
Anticoagulant therapy is effective for the management
of acute VTE and for the prevention of recurrent events
and death associated with recurrent VTE [1,3]. For half
a century, the standard therapy for patients with VTE
has been the administration of heparin, overlapped and
followed by a vitamin K antagonist (VKA) [1]. This
regimen is effective but has several limitations, such as
requirement for laboratory monitoring and dose ad-
justments, a narrow therapeutic window, and inter-
action with other drugs and foods [1,4]. Recently, new* Correspondence: norikoitabashi@gmail.com
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unless otherwise stated.direct oral anticoagulants (DOACs), such as dabiga-
tran, rivaroxaban, apixaban and edoxaban, which were
developed for stroke prevention in the context of atrial
fibrillation [5], have been shown to be effective for the
treatment of VTE [6,7]. Rivaroxaban offers a simple,
single-drug approach for initial intensive treatment,
with high-dose rivaroxaban administered for 3 weeks
followed by administration of standard dose rivaroxa-
ban [8]. In the EINSTEIN-DVT [9] and EINSTEIN PE
[4], this regimen showed no inferiority and no increase
in adverse events when compared with standard therapy
(low-molecular weight heparin [LMWH] with VKA).
Following these results, the J-EINSTEIN-DVT and -PE
studies have been conducted in Japan [10]. These studies
are open-label, randomized, multicenter trials that com-
pared oral rivaroxaban alone with standard therapy in
Japanese patients with DVT or PE. We participated in
these studies and enrolled several patients. One patient
with massive proximal DVT was assigned to rivaroxaban
15 mg twice-daily and showed marked improvement
during the first 3 weeks of therapy without any adverse
effects including minor bleeding.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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A 77-year-old male was admitted to our hospital due to
left lower limb swelling with heat sensation and redness.
These symptoms had appeared 2 days prior to hospital
admission. Five months before admission, he was diag-
nosed with polymyalgia rheumatica syndrome and started
treatment with prednisolone 10 mg per day. He had no
previous history of thrombosis and no family history sug-
gestive of inherited thrombophilia. His major risk for VTE
was advanced age, but he did not have any other risks,
such as obesity, cancer, surgery, immobilization or recent
long travel. At the time of arrival to our Emergency
Department, his entire left leg was swollen and showed
pitting edema with mild pain. Blood pressure was
164/78 mmHg, and pulse of 102 bpm. Respiratory rate
was 12/min, and arterial oxyhemoglobin saturation
was 96% at room air. Plasma D-dimer level was high
(45.0 μg/mL) while serum protein level, renal function
and liver function were normal. Multi-detector com-
puted tomography (MDCT) showed massive deep vein
thrombosis from the lower edge of inferior vena cava
to the lower leg veins (Figure 1). This patient had a
congenital anomaly of the iliac vein in which the left
external iliac vein (EIV) and left internal iliac vein
(IIV) separately branched off from the inferior vena
cava without a left common iliac vein (Figure 1A). The
left EIV was compressed by the abdominal aorta and the
fifth lumbar vertebra (Figure 1A and B). The thrombosis
extended from the calf veins to the compressed site, sug-
gesting a variant of iliac vein compression syndrome
(May-Thurner syndrome) [11,12]. The left IIV also had a
large thrombus (Figure 1C and D). The patient did not
have any symptom related with PE and his lung
MDCT did not show any embolism in the pulmonary
arteries. Compression venous ultrasonography also showed
massive DVT from the left iliofemoral level to the lower
leg level, but slight venous flow was observed by color
Doppler at the level of the left common femoral vein.
A diagnosis of DVT was made, and the patient was im-
mediately started on intravenous unfractionated heparin
administration. The patient subsequently provided written
informed consent to participate in the J-EINSTEIN study
[10]. We screened thrombophilia including antiphospholi-
pid syndrome, protein S/C deficiency, fibrinogen and anti-
thrombin III abnormality, but could not find any cause of
DVT except steroid administration. Then, prednisolone
dose was reduced to 7.5 mg. Since the patient was
assigned to begin rivaroxaban therapy on the second
day of hospitalization, a 15-mg dose of rivaroxaban admin-
istration was given 4 hours after termination of heparin,
according to the study protocol. His left leg swelling
showed progressive reduction on a daily basis in response
to rivaroxaban 15 mg twice-daily. After 2 weeks of treat-
ment, the patient was discharged from our hospital, as hissymptoms and leg swelling had markedly improved. We
did not use any compression therapy because the symptom
improvement was observed from initial several days. The
circumference of the left femoral region had decreased
from 50.6 cm to 45.8 cm over the 2 weeks of initial treat-
ment, and plasma D-dimer level decreased to 3.9 μg/mL
by the time of hospital discharge. Surprisingly, the massive
DVT in his left leg had almost completely disappeared
according to MDCT performed on day 22 of the treat-
ment (Figure 2). Compression venous ultrasonography at
day 25 only showed a small thrombus at the left popliteal
vein. As per protocol, we switched the dose of rivaroxaban
to 15 mg per day following 3 weeks of intensive therapy.
We monitored his clinical symptom and physical examin-
ation every month and continued the study drug for 1 year.
Neither bleeding nor recurrence of thrombosis occurred
over the entire clinical course of the treatment.
Discussion
The present report described a case of a patient with
DVT who showed marked improvement in response to
oral rivaroxaban treatment during the initial intensive
dose period. This patient had a massive thrombus ex-
tending from the left iliac vein to the lower leg veins
with iliac vein compression syndrome. He had typical
symptoms of DVT for 2 days but had no obvious risk
factors for acute DVT except for steroid administration.
He was enrolled in the J-EINSTEIN study and was
assigned to receive rivaroxaban 15 mg twice daily. After
starting treatment, his leg edema progressive decreased
on a daily basis. CT scan on day 22 revealed that the
iliac vein thrombosis had almost completely disap-
peared. No bleeding event occurred during the course
of treatment.
Iliac vein compression syndrome (May-Thurner syn-
drome) is most commonly seen in women at 30 to 50 years
of age [12]. The right common iliac artery crosses over the
left common iliac vein and then runs adjacent to the right
iliac vein. Typically, the left iliac vein is compressed be-
tween the right common iliac artery anteriorly and the sa-
cral promontory or the fifth lumbar vertebra posteriorly
just before the iliocaval junction [12]. This case did not
have a left common iliac vein and had venous return dir-
ectly from the left external iliac vein to the vena cava at an
unusually proximal position. We assume that this anomaly
contributed to the development of iliac compression by
the abdominal aorta. Aging-related atherosclerosis and
vertebra deformity might anatomically augment the vein
compression in this anomaly.
Proximal iliofemoral DVT causes PE in about half of
cases. This condition can also lead to chronic venous insuf-
ficiency and recurrent thrombosis [2]. Compression of the
iliac vein has been documented in about 50% of patients
with left iliac DVT [12] and may require treatment via
Figure 1 Multi-detector computed tomography (MDCT) on admission. A and B. Transverse plane (A) and coronal plane (B) at the ilio-cava
junction level. Left external iliac vein (lt EIV) branches off directly from the inferior vena cava. The left EIA is compressed by the abdominal
aorta (*) with thrombus; C to E. Transverse plane (C and E) and coronal plane (D and F) at the iliofemoral vein level. Lt EIV, right common
iliac vein (rt CIV), left internal iliac vein (lt IIV) and left femoral vein (let FV) have thrombi; G. left popliteal vein thrombus (white arrow); H. thrombi
of left lower leg veins/soleal veins (white arrows).
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loon venoplasty and stent implantation [12,13]. However,
some degree of compression of the left common iliac vein
may also be an incidental finding [14]. Although our case
was affected by the iliac vein compression, the decrease in
thrombus size in response to medical therapy without the
need for invasive approaches suggests that iliac vein com-
pression did not have a significant effect on the response
to medical therapy. After 3 weeks of high-dose treatment,the rivaroxaban dose was decreased to complete a 1-year
course. The patient did not experience DVT recurrence
despite persistent iliac compression.
Rivaroxaban is an oral Xa inhibitor that is as effective as
standard anticoagulant therapy (i.e., heparin and warfarin)
for VTE treatment [4,9]. Earlier studies showed that an in-
tensive regimen (15 mg twice-daily) during the first 3 weeks
is necessary to achieve an effective higher trough levels and
earlier steady state and thereby contribute to more effective
Figure 2 MDCT at day 22. A and B. Transverse plane (A) and coronal plane (B) at the ilio-cava junction level. * Abdominal aorta. Iliac vein
compression persists, but the contrast defect has disappeared (white arrow); C to E. Transverse plane (C and E) and coronal plane (D and F) at
the iliofemoral vein level. Thrombi shown in Figure 1 have disappeared (white arrow); G. Absence of the left popliteal vein thrombus (white arrow);
H. Absence of the left lower leg vein thrombus (white arrows).
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designed to examine the effectiveness of rivaroxaban for
Japanese patients with VTE [10]. A 30-mg dose per day is
two times higher than the dose of standard anticoagulant
therapy (15 mg per day) for atrial fibrillation in Japan. This
high-dose intensive regimen, however, did not cause any
significant adverse bleeding events, even in Japanese
patients [10].An important point in VTE treatment is to consider the
risk and benefit of anticoagulant therapy, but the effective-
ness of the selected therapy for thrombus regression
should be considered as well [2,3,15]. Long-standing DVT
related to insufficient anticoagulation might increase the
risk of postthrombosis syndrome and organization of the
thrombus [2,15]. Thrombolysis therapy is associated with
a substantial effect on thrombus regression in massive
Koitabashi et al. Thrombosis Journal  (2015) 13:13 Page 5 of 6DVT [2,15], while bleeding risk is definitely increased in
general [16,17]. Since the imaging technique for quantify-
ing thrombus is limited, there was no comparable data for
anticoagulant therapy in terms of ability for thrombus re-
gression. Generally, standard anticoagulant therapy is not
quite effective for thrombus regression when compared
with thrombolysis therapy [18,19]. Although distal
DVT, including those at the femoral level, may spon-
taneously regress with only anticoagulant therapy [19],
the actual effect of the anticoagulant on DVT regression
at the level of the iliac vein remains unclear. Surprisingly,
the patient in the present case experienced nearly 100%
thrombus regression over the first 3 weeks of therapy
and did not experience recurrence, implying that the
high-dose regimen might be better treatment than
standard therapy.
In J-EINSTEIN study, regression of thrombus was more
frequently observed in rivaroxaban-treated group com-
pared with heparin-warfarin-treated group [10]. Khalafallah
et al. showed a Caucasian case with a remarkable regres-
sion of bilateral extensive DVT by rivaroxaban suggesting
that the efficacy would not be unique for Japanese patients
[20]. However, since follow-up CT scan within a month
from initial DVT treatment is generally uncommon in
Western countries, there were few reports to show the
early phase DVT regression induced by anticoagulant
without thrombolysis. It would be worth to compare
rivaroxaban and standard anticoagulants in terms of
the thrombus-regressive effect in large international
cohort in future.
There are several possible reasons for the marked effect
of rivaroxaban in the present case. One reason is that
the treatment was started during the early phase of
DVT [3]. Another reason might be spontaneous recanaliza-
tion [19], as compression venous ultrasonography showed
slight venous flow even before treatment. Thrombus regres-
sion in response to anticoagulant therapy is more difficult to
achieve in the context of an occluding thrombus. Recent
several reports in left atrium or portal vein thrombosis indi-
cate that rivaroxaban might be able to resolve clots rapidly
[21-23]. A basic study showed that rivaroxaban-mediated
suppression for thrombin generation leads a looser clot
which is more degradable by fibrinolytic enzymes [24]. This
mechanism may explain its efficacy in promoting the dissol-
ution of the thrombus.
At present, the results of the trials using DOACs in
the treatment of VTE showed that these agents are
non-inferior and possibly safer than the standard heparin-
warfarin regimen [3]. However, in several specific condi-
tions such as cancer, pregnancy and renal insufficiency, the
DOAC-use for VTE patents is limited [3]. Experience with
DOACs in large patient populations is lacking so far
and real-world patient outcome will need to be care-
fully monitored.Conclusions
In summary, this report showed remarkable efficacy and
safety of initial intensive treatment with rivaroxaban in a
patient with massive thrombus. Further, no bleeding side
effects were noted. While large-scale and precise investi-
gation comparing standard treatment and new oral anti-
coagulants are required to validate these observations,
this case suggests that rivaroxaban has the potential to
replace conventional therapy with heparin and oral VKA
for patients with massive DVT.
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